We have located links that may give you full text access.
Orexin 2 receptor antagonism sex-dependently improves sleep/wakefulness and cognitive performance in tau transgenic mice.
British Journal of Pharmacology 2023 August 9
BACKGROUND AND PURPOSE: Tau pathology contributes to a bidirectional relationship between sleep disruption and neurodegenerative disease. Tau transgenic rTg4510 mice model tauopathy symptoms including sleep/wake disturbances, which manifest as marked hyperarousal. This phenotype can be prevented by early transgene suppression, however, whether hyperarousal can be rescued after its onset is unknown.
EXPERIMENTAL APPROACH: Three chronic (8-week) experiments were conducted with wild-type and rTg4510 mice after the age of onset of hyperarousal (4.5 months): 1) Tau transgene suppression with doxycycline (200 ppm); 2) Inactive phase REM sleep enhancement with the dual orexin receptor antagonist suvorexant (50 mg/kg/day); or 3) Active phase NREM and REM sleep enhancement using the selective orexin 2 (OX2 ) receptor antagonist MK-1064 (40 mg/kg/day). Sleep was assessed using polysomnography, cognition using the Barnes maze, and tau pathology using western blot and/or immunohistochemistry.
KEY RESULTS: Tau transgene suppression improved tauopathy and hippocampal-dependent spatial memory, but didn't modify hyperarousal. Pharmacological rescue of REM sleep deficits did not improve spatial memory or tau pathology. In contrast, normalising hyperarousal by increasing both NREM and REM sleep via OX2 receptor antagonism restored spatial memory, independently of tauopathy, but only in male rTg4510 mice. OX2 receptor antagonism induced only short-lived hypnotic responses in female rTg4510 mice and did not improve spatial memory, indicating a tau- and sex-dependent disruption of OX2 receptor signalling.
CONCLUSIONS AND IMPLICATIONS: Pharmacologically reducing hyperarousal corrects tau-induced sleep/wake and cognitive deficits. However, tauopathy causes sex-dependent disruptions of OX2 receptor signalling/function, which may have implications for choice of hypnotic therapeutics in tauopathies.
EXPERIMENTAL APPROACH: Three chronic (8-week) experiments were conducted with wild-type and rTg4510 mice after the age of onset of hyperarousal (4.5 months): 1) Tau transgene suppression with doxycycline (200 ppm); 2) Inactive phase REM sleep enhancement with the dual orexin receptor antagonist suvorexant (50 mg/kg/day); or 3) Active phase NREM and REM sleep enhancement using the selective orexin 2 (OX2 ) receptor antagonist MK-1064 (40 mg/kg/day). Sleep was assessed using polysomnography, cognition using the Barnes maze, and tau pathology using western blot and/or immunohistochemistry.
KEY RESULTS: Tau transgene suppression improved tauopathy and hippocampal-dependent spatial memory, but didn't modify hyperarousal. Pharmacological rescue of REM sleep deficits did not improve spatial memory or tau pathology. In contrast, normalising hyperarousal by increasing both NREM and REM sleep via OX2 receptor antagonism restored spatial memory, independently of tauopathy, but only in male rTg4510 mice. OX2 receptor antagonism induced only short-lived hypnotic responses in female rTg4510 mice and did not improve spatial memory, indicating a tau- and sex-dependent disruption of OX2 receptor signalling.
CONCLUSIONS AND IMPLICATIONS: Pharmacologically reducing hyperarousal corrects tau-induced sleep/wake and cognitive deficits. However, tauopathy causes sex-dependent disruptions of OX2 receptor signalling/function, which may have implications for choice of hypnotic therapeutics in tauopathies.
Full text links
Related Resources
Trending Papers
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Revascularization Strategy in Myocardial Infarction with Multivessel Disease.Journal of Clinical Medicine 2024 March 27
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app